The high expression of Ano1 was significantly associated with longer OS in patients with PR-positive (p = 0.026), or HER2-negative (p = 0.010), but not HER2-postive (p = 0.478), breast cancer (Fig 5B–5F). Here, ANO1 is linked to breast carcinoma.